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 Abstract. The aetiological agent of chronic hepatitis C is the
hepatitis C virus. The hepatitis C virus is spread by parenteral
transmission of body fluids, primarily blood or blood products.
In 1989, after more than a decade of research, HCV was
isolated and characterised. The hepatitis C viral genome is a
positive-sense, single-stranded RNA molecule approximately
9.4 kb in length, which encodes a polyprotein of about
3100 amino acids. There are 6 main genotypes of HCV, each
further stratified by subtype. In 1994, a cohort of women was
identified in Ireland as having been iatrogenically exposed to
the hepatitis C virus. The women were all young and exposed
as a consequence of the receipt of HCV 1b contaminated
anti-D immunoglobulin. The source of the infection was
identified as an acutely infected female. As part of a voluntary
serological screening programme involving 62,667 people,
704 individuals were identified as seropositive for exposure
to the hepatitis C virus; 55.4% were found to be positive for
the viral genome 17 years after exposure. Of these women
98% had evidence of inflammation, but suprisingly, a
remarkable 49% showed no evidence of fibrosis. Clinico-
pathology and virological analysis has identified associations
between viral load and the histological activity index for
inflammation, and, between inflammation and levels of the
liver enzyme alanine aminotransferase. Infection at a
younger age appears to protect individuals from progression
to advanced liver disease. Molecular analyses of host
immunogenetic elements shows that particular class II human
leukocyte associated antigen alleles are associated with
clearance of the hepatitis C virus. Additional class II alleles
have been identified that are associated with stable viraemia
over an extended period of patient follow-up. Although,
investigation of large untreated homogeneous cohorts is
likely to become more difficult, as the efficacy of anti-viral
therapy improves, further investigation of host and viral
factors that influence disease progression will help provide an
evidence based approach were realistic expectations
regarding patient prognosis can be ascertained.
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1. Epidemiology and natural history of hepatitis C virus
infection
Chronic hepatitis C is a ubiquitous disease, affecting
approximately 170 million individuals worldwide (1). The
global prevalence of the hepatitis C virus (HCV) ranges from
less than 0.5% (Scandinavia, USA, Western Europe) to greater
than 44% (Northwest Egypt and southern Cameroon) (2).
The HCV is spread by parenteral transmission of body fluids,
primarily blood or blood products. In 1989, after more than a
decade of research, HCV was isolated and characterised (3).
The hepatitis C viral genome is a positive-sense, single-
stranded RNA molecule approximately 9.4 kb in length, which
encodes a polyprotein of about 3100 amino acids (4). This
polyprotein is cleaved into functional proteins by cellular and
viral proteases. There are 6 main genotypes of HCV, each
further stratified by subtype (5). Hepatitis C virus exists as a
heterogeneous mixture of closely related viruses called
quasispecies. Substantial evidence indicates that HCV geno-
type is clinically important with respect to efficacy of interferon
therapy, the likelihood of response to antiviral therapy appears
to be associated with the degree of quasispecies diversity (6-9).
Additionally, mutations in the viral population likely contribute
to the emergence of resistance during anti-viral therapy.
Current estimates of medical and work-loss costs of
HCV related acute and chronic liver diseases are greater than
$600 million per annum in USA (10). Ireland, like many other
countries is no stranger to the HCV, has been effected by the
considerable socio-economic cost of the HCV. The Hepatitis
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Compensation Tribunal set-up in response to the iatrogenic
infection of Irish citizens with HCV has from 1996 to 2000
costs of approximately 380 million Euro (11). HCV associated
end-stage liver disease is the most frequent indication for liver
transplant among adults (10). Since, most HCV infected
individuals are relatively young (18-40 years) the number of
deaths attributable to HCV related disease is likely to increase
substantially in the next two decades.
Serological evidence of exposure to the HCV can now be
identified by both enzyme linked immunosorbent and
recombinant immunoblot assays (12). Detection of viral nucleic
acid is possible using an array of nucleic acid technologies
(12). Acute hepatitis C is often mild and asymptomatic.
Chronic hepatitis C, is an indolent disease characterised by
hepatic inflammation and hepatocellular necrosis, may progress
to cirrhosis and/or hepatocellular carcinoma (1,13,14). Our
understanding of why only 45-20% of individuals resolve a
primary infection is limited, but recent findings of human
leukocyte associated antigen correlations with viral clearance
may offer insights into how potential vaccines can be
developed (15-25).
Many studies have attempted to define correlations between
the indices of disease activity in an endeavour to define the
natural progression of chronic hepatitis C (26-32). However,
there is considerable heterogeneity with regard to the finding
of associations between biochemical, histological, and viro-
logical markers of disease. This conflict is likely to be due, in
large part, to the heterogeneity of patient groups with respect
to the variation in disease duration, differences between size
and ‘relative fitness’ of individual viral inocula, mixed geno-
type study groups, mixed gender study groups, co-existence
of hepatotropic infections and immunomodulatory viruses
such as the human immunodeficiency virus (HIV). Defined
homogeneous cohorts offer the best opportunity to clarify the
true natural progression of hepatitis C infection. Globally, there
are two relatively homogeneous cohorts of individuals infected
with HCV 1b from contaminated anti-D immunoglobulin
during the late 1970s (15,16). An additional cohort where
long-term concurrent prospective evaluation of disease
activity is under investigation is the Veterans Administration
(VA) study of transfusion-associated hepatitis conducted by
Seeff et al (33). The value of these study groups is that the
time of infection has been established, the anti-D cohorts are
ethnically homogeneous, in particular the anti-D cohorts are
all infected with the same genotype/subtype of the HCV,
infection was from a single donor, and a high percentage have
undergone and are likely to undergo continuous long-term
prospective follow-up.
2. The Irish paradigm on the natural progression of
hepatitis C virus infection
An investigation in a homogeneous patient population infected
with HCV 1b
Background to iatrogenic infection of Irish women in Ireland
with HCV 1b from contaminated anti-D immunoglobulin. In
1993 a group of Irish individuals were identified as seropositive
for exposure to the hepatitis C virus during an investigation of
the prevalence of hepatitis C seropositivity in the Irish blood
donor population. In total, 29 individuals out of a total of
100,000 donors screened, were seropositive (34). Fifteen were
female and 14 were male. Of the 15 female individuals 13
were found to be Rhesus negative. The finding of nearly 87%
Rhesus negative individuals in this small group of individuals
was inversely proportional to the observed frequency for this
marker in the Irish population. This observation prompted the
initiation of a lookback study to identify any infectious or
potentially infectious commonality among these 13 women.
Twelve of the 13 individuals were found on lookback to have
been in receipt of anti-D immunoglobulin during 1977-78.
Subsequent molecular screening for viral nucleic acid revealed
that batches of anti-D immunoglobulin used in Ireland during
the 18 month period from May 1977 to November 1978 were
found to be contaminated with HCV genotype 1, subtype b
(16,35,36). Molecular evidence for transmission via HCV 1b
contaminated anti-D immunoglobulin (HAD-1b) was also
provided by comparison of sequences from 100 individuals for
part of the NS5 region of the viral genome and virus isolated
from implicated batches of anti-D immunoglobulin 17 years
after the exposure event (37). The iatrogenic infection of
Rhesus negative women in May 1977 to November 1978
presented the scientific and medical communities in Ireland
with an globally unique opportunity to study, the natural history
of hepatitis C infection, and, the viral and host factors that
affect the rate of disease progression.
Further investigation discovered that the sole source of the
infectious plasma used to harvest the anti-D immunoglobulin
was documented to be from a female individual who
experienced a jaundice episode after transfusion, 4th
November 1976 (34,36). In an attempt to identify all possible
recipients of potentially infectious anti-D immunoglobulin an
anti-HCV serological screening programme was instituted in
the Republic of Ireland (36). In total, 62,667 individuals were
screened in a voluntary nation-wide screening programme (16).
Seven hundred and four individuals were identified as having
evidence of past exposure to HCV. Of these individuals 55.4%
were subsequently identified as being positive for the HCV
genome, all were confirmed as HCV 1b.
Histological disease progression 17 years post-infection.
Extensive evaluation of 376 (96%) of those who were positive
for the viral genome indicated that approximately 33% had at
least one other risk factor for hepatitis C, in addition, to
exposure to HCV 1b contaminated anti-D immunoglobulin
(16,38). The most common other risk factor was blood
transfusion at 17%. The median ALT level was 42 IU/ml.
Histologic appraisal of 93% (n=363) of those who were PCR
positive for HCV indicated that a remarkable 49% had no
evidence of fibrosis and only 2% had evidence of probable or
definite cirrhosis. In the absence of competing aetiologies for
liver disease, hepatitis C infection appears to progress slowly
in this study group infected with HCV 1b. The relatively
benign outcome of this infection, in this cohort, may reflect
the small size of viral inoculum, the relative young age at
infection, the observation that disease progression is slower
in females, or, that further concurrent prospective follow-up
is needed to determine the natural progression of what is an
infection of several decades. Interestingly, of the 2% (n=7) with
evidence of cirrhosis in the Irish anti-D cohort, two individuals
reported excessive alcohol intake. The significance of the
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findings reported by Kenny-Walsh are that they for the first
time defined what is likely to be the natural progression of
chronic hepatitis C, in the absence of competing aetiologies
for liver disease and in a cohort where alcohol consumption is
low. Investigation of a German cohort of women infected
through HCV 1b contaminated anti-D immunoglobulin
reported similar histological findings to Kenny-Walsh (16).
Clinicopathology and virology of HAD-1b infected individuals.
Several investigators have defined the clinicopathological and
virological features of chronic hepatitis C infection. However,
there has been considerable heterogeneity with regard to the
ascribed associations. The dichotomy between individual
investigations is likely to be the result of variation in viral
genotype, variation in disease duration, combination of
associated risk factors for more rapidly progressing liver
disease such as alcohol, hepatitis B virus co-infection, HIV,
variance in the age at infection and the probably risk factor of
multiple exposures. The strength of the Irish anti-D cohort is
the ability to control for variables that impact on the natural
history of HCV infection. In a study population of 77 PCR
positive individuals from the anti-D cohort, we identified an
association between i) HCV RNA titres and the degree of
inflammation, and ii) the degree of inflammation and serum
ALT levels, 17 years post infection (32). Correlative analysis
between the indices of disease activity by its nature has to
assume that the ‘snap-shot’ view of any disease is
representative of the overall progression. The observed
associations between clinicopathological and virological
indices of disease represent a window into the natural history
of this infection. These correlations may not withstand
prospective evaluation as there is currently no evidence that
disease progression in chronic hepatitis C is linear. Mechanistic
explanations for many of the observed correlations are
currently unclear. The mechanisms of HCV-induced liver
damage are not clearly defined. However, hepatic injury is
likely to be, in part, immune mediated because HCV is not
obviously cytopathic. The evidence that HCV-associated
hepatic injury is immune mediated is primarily indirect: i)
treatment with corticosteroids and other immunosuppressive
agents can reduce ALT levels even though viral load increases
(39,40); ii) HCV-infected liver transplant patients, when
immunosuppressed, have very high viral titres but can remain
asymptomatic (40); iii) activated CD8+ T cells can migrate
from the periphery to the liver and initiate tissue damage (41)
and iv) viral replication can occur in the absence of evidence
of liver cell damage (42). The immunologically mediated
necroinflammatory injury see in hepatitis C infection is some
what akin to the situation observed in chronic hepatitis B
infection (43). Suggestive evidence of a role for HCV core
and NS3 protein in development of hepatocellular carcinoma
may indicate that perhaps the gene products of HCV have
oncogenic potential (44-47).
Host-virus interaction. Host factors that influence disease
progression include age at exposure, excessive alcohol
consumption, and the presence of competing aetiologies for
liver disease. In addition, host-dependent genetic factors,
(specifically, HLA class II), have been shown to be related to
viral clearance in several studies (20-23,25,48-51).
We undertook an investigation of the HLA class II elements
associated with persistence or clearance of HAD-1b in a study
population of 156 from the Munster region of Ireland. All
156 individuals were confirmed RIBA positive, with 46% of
these individuals (n=72) positive for the HCV by RT-PCR.
HLA DRB1 and DQB1 status was molecularly defined by high
resolution reverse line probe hybridisation methodologies (22).
Several factors were identified as having an association with
clearance of HAD-1b, specifically, DRB1*01 (excluding the
DRB1*0103) and the extended haplotype of DRB1*0701/
DQB1*0501. Two other independent studies on persistence
and clearance in HAD-1b exposed individuals have reported
the association of DRB1*01 with clearance of HCV (21,23).
Thio et al also reported an association of HLA DRB1*01
alleles with clearance of HCV (18). In our particular study
group, no association between individual alleles of the DQB1
locus and persistence or clearance was found. However,
McKiernan et al identified DQB1*0301 as having an
association between exposure to HAD-1b and resolving
infection (21). This finding is in agreement with that reported
by others (20,49,52). Globally, the variance of association
between different study populations is likely to reflect several
important factors i) the allelic possession frequency between
ethnically different populations (18,53), ii) differences between
populations or skewing of results caused by comparisons
between infected individuals and unexposed controls, as
opposed to individuals who were exposed to HCV and either
cleared the infecting virus or developed chronic persistent
infection (20), and iii) mixed genotype study populations with
variation in disease duration (18,49).
An examination of possible host factors that may influence
the dynamics of hepatitis C viraemia revealed that particular
HLA class II alleles, or genes in linkage disequilibrium with
these alleles, were associated with either stability of viraemia
or dynamic change in viral load during the study period for
this study group (54). High resolution molecular analysis of
the HLA class II DRB1 and DQB1 loci revealed that changes
in viraemia were associated with DRB1*15/DQB1*0602
haplotype. It was found that possession of DRB1*0701/
DQB1*0201 haplotype was associated with relatively stable
viral load over an extended period of patient follow-up. The
mean fold increase per annum during the study period was
approximately 1.3-fold increase during the study period for
the latter haplotype. Those individuals who were in possession
of DRB1*15/DQB1*0602 were found to have a mean fold
increase in viral load per annum of 6.1. The finding of a
dynamically changing viral load for those individuals in
possession of the DRB1*15/DQB1*0602 haplotype may reveal
a window of transformation in the natural history of this
infection that superseded a period where the dynamic fitness
of the viral quasispecies was set a presumptive zero. The
significance of these data is that it shows that host genomic
factors can influence the magnitude of hepatitis C viraemia.
Definition of those viral and host factors associated with
stable or changing viral load may offer opportunities for the
manipulation of viraemia to create a clinically advantageous
arena for improving the efficacy of current and future anti-
viral therapies.
Person-to-person variability in blood levels of HCV RNA
is likely to result from a dynamic equilibrium between the
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host factors that influence the rate of i) viral clearance, ii)
elimination of infected cells and iii) the viral factors that
influence the rate of infection of naive hepatocytes and iv)
factors that influence the efficiency of production of infection
competent daughter virions. In a study aimed at isolating the
determinants of viral load Thomas et al examined viral loads
in 969 persons who acquired HCV infection in the context of
injection drug use (55). However, greater than 90% of the
person-to-person HCV RNA level variability could not
explained by the sociodemographic factors of HCV and HIV
co-infection, HCV and non-HIV co-infected individuals,
ongoing hepatitis B infection, age and the absence of needle
sharing. A few studies have tried to elucidate possible hepatitis
C viral genomic sequences associated with fluctuations in
hepatitis C viral load. Terazawa et al, suggested that
mutations in the interferon sensitivity determining region
(ISDR) are associated with changes in viral load over a
relatively short period of time (56). These findings are
suggestive of a biologically relevant phenotype associated
with changes in viral load. However, the study group was
relatively small, reducing the significance of the inference.
Another Japanese study by Hashimoto et al, looked at the
associative relationship between the inferred amino acid
sequence of the hypervariable region 1 (HVR I) and the ISDR
and fluctuations in viral load, but found no significant
association over a 1-2 year period of patient follow-up (57).
This dichotomy between these two Japanese studies, is likely
due to heterogeneity of patient population, sequence
heterogeneity of the infecting viruses, although both studies
were of individuals infected with HCV 1b, and variance in
the duration of disease.
Interperson variability in viraemia was investigated in the
HAD-1b group of 47 patients (58). None of the patients
included in the study had received anti-viral therapy. A
statistically significant correlation between age at exposure to
HAD-1b and baseline viraemia at initiation of the study was
observed. Those infected at a younger age tended to have
much lower viraemia than those of more advanced years. If
low viral load is associated with lower indices of disease
activity this may explain, in part, why infection at a younger
age ‘protects’ from rapidly advancing disease. The rate of
change of viraemia during the study period was negatively
correlated with the baseline viral load {rate of change was
defined as the change between the first and last log10 HCV
levels divided by the follow-up time between baseline and last
follow up: rate of change of viral load was calculated using;
rate of change = log10 [HCV (Tlast) - log10 HCV (Tfirst)]/
[Tlast - Tfirst]}. Thus, individuals who had a high viral load
at baseline were found to have a slower rate of change of viral
load per annum, than, those who had low baseline viraemia.
The competitive exclusion principle may help explain, in part,
these observations. In essence, the viral load set point at any
given time is the result of the dynamic equilibrium between
viral production and clearance (59). Stability of viral load
between two time points is likely to reflect a situation where
the fitness of the viral swarm fulfils the Red Queen Hypothesis.
Displacement events that give rise to changes in viral fitness
can perturb this dynamic equilibrium engaging the competitive
exclusion principle (60-62). Thus, if a displacement event
gave rise to an increase in ‘fitness’ of the viral swarm then
the downstream effect of this is likely to be an increase in
production of daughter virions and/or an increase in viral
infectivity. The efficacy of the immune response to these ‘new’
antigenically different virions would of course affect the
overall outcome of this displacement event. A new equilibrium
is then likely to be established and the relative fitness of the
population stabilises and a new set point where the balance
between the advantages and deleterious mutations is effectively
set at zero. Of course, the phenomenon of molecular memory
in the viral quasispecies could be a disadvantageous event as
immune memory previously established could open new
avenues for combating this viral infection (63). As is evident
from the few studies that have investigated the natural variation
in hepatitis C viral load additional host and viral factors, yet
to be defined, are likely to influence this dynamic.
3. Conclusions and remarks
The natural progression of chronic hepatitis C infection is not
fully ascertained. There is conflicting data regarding the
percentage of individuals who are infected who will ultimately
have an acute resolving infection. Initial data suggest that this
could be as low as 15%, but more recent Irish cohort studies
suggest that this may be as high as 50%. There is a hetero-
geneity of opinion regarding the long-term outcome of this
chronic infection ranging from the belief that progression to
cirrhosis and/or hepatocellular carcinoma is the normal course,
to the belief that progression is indolent, resulting in mild to
moderate disease in most individuals where development of
cirrhosis is uncommon during the first two decades of the
infection and where external factors (hepatitis B co-infection,
HIV, alcohol) will result in a more rapidly progressing disease.
Strategies used to determine the natural history of hepatitis C
includes the retrospective, prospective and the combination
study of retrospective/prospective cohort studies. Of course
referral bias to specialist centres is an issue which may skew our
understanding of the progression of this disease. Progression
of liver disease in chronic hepatitis C is effected by both host
(duration of disease, age at infection, gender, co-existence of
hepatotrophic viral diseases, co-infection with immuno-
modulatory viruses, immunogenetic background) and viral
factors (genotype, viral load, quasispecies diversity, patho-
genicity of viral isolate).
The investigation of hepatitis C viral infection in Ireland
advances the following paradigm. That hepatitis C viral
infection with genotype 1b, is likely to be resolved in nearly
50% of individuals who have evidence of past exposure.
Histological progression nearly 20 years post-infection, shows
that most individuals will have inflammation of the liver
parenchyma and that nearly half of those with chronic infection
show no evidence of fibrosis/cirrhosis. Of those with fibrosis
only a very small percentage will progress to develop probable
or definite cirrhosis. Abstinence from alcohol or minimal
intake reduces the progression to cirrhosis. Infection at a
younger age protects from progression to advanced liver
disease is now evident from the investigation of the anti-D
cohort. The set point of viraemia also appears to be influenced
by the age at exposure. Those individuals who are exposed in
early adulthood showed lower baseline viral load 17-19 years
post-exposure of HCV 1b. Host immunogenetic factors
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associated with clearance of HCV have been described. Host
immunogenetic factors seem to be involved in protection from
dynamic changes in viraemia. However, not all the observed
changed in viral load over an extend period of patient follow-
up could be accounted for by host HLA profile.
More research into the natural history of hepatitis C is
required. Defined cohorts who are prospectively evaluated
offer the best opportunity to define the natural progression of
this chronic liver disease. Although, investigation of large
untreated cohorts is likely to become more difficult as the
efficacy of anti-viral therapy improves it will be essential to
define those factors that will predict long-term outcome.
However, most importantly, a greater understanding of the
natural progression of hepatitis C and the factors that impinge
on progression will provide for an ‘evidence based’ medical
approach whereby realistic expectations regarding outcome
can be achieved.
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